TY - JOUR
T1 - Targeting fatty acid synthase
T2 - Potential for therapeutic intervention in Her-2/neu-overexpressing breast cancer
AU - Menendez, Javier A.
AU - Lupu, Ruth
AU - Colomer, Ramon
PY - 2005/7
Y1 - 2005/7
N2 - Fatty acid synthase (FAS)-catalyzed de novo fatty acid biosynthesis, an anabolic energy-storage pathway largely considered of minor importance in humans, actively contributes to the cancer phenotype by virtue of its ability to specifically regulate the expression and activity of Her-2/neu (erbB-2) oncogene. First, a positive correlation between high levels of FAS expression and/or activity and the amplification and/or overexpression of Her-2/neu oncogene exists in human breast cancer cell lines. Second, Her-2/neu overexpression stimulates the activity of FAS gene promoter and ultimately mediates increased endogenous fatty acid biosynthesis, while this Her-2/neu-induced upregulation of breast cancer-associated FAS is inhibitable by anti-Her-2/neu antibodies such as trastuzumab (Herceptin™). Third, pharmacological inhibition of FAS activity negatively regulates the expression and tyrosine-kinase activity of Her-2/neu-coded p185Her-2/neu oncoprotein.
AB - Fatty acid synthase (FAS)-catalyzed de novo fatty acid biosynthesis, an anabolic energy-storage pathway largely considered of minor importance in humans, actively contributes to the cancer phenotype by virtue of its ability to specifically regulate the expression and activity of Her-2/neu (erbB-2) oncogene. First, a positive correlation between high levels of FAS expression and/or activity and the amplification and/or overexpression of Her-2/neu oncogene exists in human breast cancer cell lines. Second, Her-2/neu overexpression stimulates the activity of FAS gene promoter and ultimately mediates increased endogenous fatty acid biosynthesis, while this Her-2/neu-induced upregulation of breast cancer-associated FAS is inhibitable by anti-Her-2/neu antibodies such as trastuzumab (Herceptin™). Third, pharmacological inhibition of FAS activity negatively regulates the expression and tyrosine-kinase activity of Her-2/neu-coded p185Her-2/neu oncoprotein.
UR - http://www.scopus.com/inward/record.url?scp=30444434391&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=30444434391&partnerID=8YFLogxK
U2 - 10.1358/dnp.2005.18.6.927929
DO - 10.1358/dnp.2005.18.6.927929
M3 - Review article
C2 - 16247515
AN - SCOPUS:30444434391
SN - 0214-0934
VL - 18
SP - 375
EP - 385
JO - Drug News and Perspectives
JF - Drug News and Perspectives
IS - 6
ER -